Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11405/nisshoshi.121.948 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature.
Melanoma Res
December 2024
Department of Medicine, School of Medicine, University of Utah.
Acquired generalized lipodystrophy (AGL) is a rare complication of immune checkpoint inhibitors (ICIs) and is associated with immune-mediated loss of adipose tissue, peripheral resistance to insulin, and serious metabolic complications. Here we report a new case of ICI-induced AGL and provide an updated literature review of published cases. We report a 39-year-old female patient treated with adjuvant pembrolizumab for stage IIIC nevoid melanoma with ICI-induced AGL.
View Article and Find Full Text PDF[ICI-induced liver injury].
Nihon Shokakibyo Gakkai Zasshi
January 2024
Department of Gastroenterology and Hepatology, Nagoya University Hospital.
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events.
Gut
December 2024
Surgery & Cancer, Imperial College London, London, UK.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) have significantly improved the treatment of liver cancers (HCC) and biliary tract cancer, enhancing survival rates and reshaping care standards.
- Despite these advancements, there is a lack of reliable predictors for patient response to ICIs, which poses risks of liver toxicity and worsening chronic liver disease.
- The article reviews the mechanisms behind the effectiveness and toxicity of ICIs in liver tumors and explores how liver health affects the outcomes of treatment, providing insights for future clinical research.
Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.
Cancer Biol Med
December 2024
Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.
Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). However, the mechanisms underlying macrophages in irAEs have not been elucidated.
Methods: An osimertinib and ICI-induced irAE mouse model was constructed.
Hepatic sinusoidal obstruction syndrome after immune-checkpoint-inhibitor therapy: when the liver sends SOS.
BMJ Case Rep
September 2024
Department of Gastroenterology and Hepatology, University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany.
A woman in her 50s presented to the hospital with new-onset jaundice and ascites. Her medical history included a melanoma of the right shoulder, diagnosed 8 months before, for which she had received four cycles of ipilimumab and nivolumab. Due to the oncological history and previous immunotherapy, an immune-checkpoint-inhibitor (ICI)-induced hepatitis was suspected, and a high-dose corticosteroid treatment was initiated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!